HIV is spread most by people with medium levels of HIV in blood, says study

October 22, 2007

People with medium levels of HIV in their blood are likely to contribute most to the spread of the virus, according to new research published today in the journal Proceedings of the National Academy of Sciences.

The study, by researchers from Imperial College London, looked at several groups of HIV-positive people in Europe, the USA and sub-Saharan Africa. It found that those with a high viral load are the most infectious group, but have only limited time to infect others, because they generally progress to AIDS quite quickly.

Viral load - a count of how many viral particles are in a person's blood - varies hugely between individuals. The higher the viral load, the more infectious a person is but the shorter their life expectancy. As a result, the study found, those with a high viral load do not contribute the most in the long run to the spread of HIV.

Those with a medium viral load are moderately infectious but remain asymptomatic for a period of about six to eight years before progressing to the symptoms of AIDS. This means they can be unaware that they have HIV for a long period of time, during which they can transmit the virus to a number of different sexual partners, and hence contribute most to the epidemic.

Dr Déirdre Hollingsworth, one of the authors of the paper from the Department of Infectious Disease Epidemiology at Imperial College, said: "Just being highly infectious isn't enough, you have to live long enough to pass the virus on. This long-term view should inform public health policy."

Despite much recent progress, effective treatment is still not widely available across sub-Saharan Africa, where most infected individuals live. One idea which has been put forward is that treatment should target the most infectious people, with high viral loads, in order to limit transmission. The results of the new study suggest that this would not be an effective plan, as the largest number of new infections is caused by people with medium viral loads.

Those with a medium viral load form the largest, most common group amongst those not receiving treatment. One reason for this could be that the virus has evolved to achieve the optimal balance between infectiousness and virulence, in order to maximise its chances of getting passed on.

Dr William Hanage, another of the authors from the same department at Imperial, commented: "It's certainly very striking that the viral loads we see most in nature are just right to make sure the virus gets transmitted as much as it can before it kills its host, which is what you would expect from evolution."

Dr Christophe Fraser, lead author of the study from the Department of Infectious Disease Epidemiology at Imperial College, added: "We now want to see whether the virus has adapted in order to allow it to infect the most people, which seems plausible given the results of our study. This would have serious implications for public health policy, because if it is true then some strategies to prevent transmission could end up making the virus more virulent by accident. While it is too early to sound the alarm, more research to prove or disprove this theory is urgently needed. That is what we are focusing on now."
-end-


Imperial College London

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.